Brain and peripheral renin-angiotensin systems are important in blood pressure maintenance. Circulating ANG II stimulates brain RAS to contribute to the increase mean arterial pressure (MAP). This mechanism has not been fully clarified, so it was hypothesized that reducing angiotensin type 1a ( 
These observations were confirmed by acute administration of losartan (20 nmol/l, 100 nl/site) in the PVN prior to short-term infusion of ANG II; the ANG II-pressor response was attenuated by 69%. In contrast, PVN Ad-AT shRNA treatment did not influence phenylephrine-induced increases in blood pressure (30 μg·kg ·min iv, 15 μl/min for 30 min). Importantly, PVN Ad-AT shRNA did not alter superior mesenteric arterial contractility to ANG II or norepinephrine; ACh-induced arterial relaxation was also unaltered. β- 
28, 33, 43).
In order for ANG II to stimulate neurally mediated increases in blood pressure, ANG II must act at angiotensin type 1 (AT ) receptors (AT Rs) in regions of the brain that recognize changes in circulating hormones, since ANG II does not cross the blood-brain barrier. However, circulating ANG II stimulates AT Rs (10) in specific regions of the brain that are devoid of a blood-brain barrier, such as the subfornical organ (SFO) (20) , organum vasculosum of the lamina terminalis (OVLT) (14) , and area postrema (18) . These structures, Effects of small intestinal glucose load on blood pressure, splanchnic blood flow, glycemia, and GLP-1 release in healthy older subjects
The area postrema in hindbrain is a central player for regulation of drinking behavior in Japanese eels important excitatory neurotransmitter in the PVN, mediating cardiovascular function through AT Rs at pre-and postsynaptic sites (6, 7, 12, 14, 21).
These responses are mediated in part through the sympathetic nervous system (8) and can be activated by circulating ANG II administered exogenously (12) or generated in pathophysiological states such as heart failure (42). In both situations, PVN angiotensinergic mechanisms contribute to blood pressure. Adenovirus encoding of AT small hairpin RNA (shRNA) has been successfully used to interfere with the expression of AT Rs (8) .
The goals of the present study were 1) to determine if AT shRNA administration into the PVN would interfere with short-term infusions of ANG II intravenously and 2) to assess the duration of effective suppression of expression of AT R protein and physiological response.
MATERIALS AND METHODS

Animals
All animal procedures were carried out in accordance to and with the approval of the Institutional Animal Care and Use Committee at Michigan State University. Upon arrival at the facility, male Sprague-Dawley rats (275-300 g;
Charles River Laboratories, Portage, MI) were housed in clear plastic boxes with wood chip bedding and allowed ad libitum access to rat chow (Teklad) and tap water. For surgical procedures, anesthesia was administered by isoflurane gas (2% in O ) unless otherwise specified. All animals were treated with postsurgical analgesics, and all surgery was performed aseptically.
Surgical Interventions
Vascular catheterization.
Animals were prepared with femoral arterial and/or femoral venous catheters, with tips in the abdominal aorta and vena cava. The catheters were tunneled subcutaneously to the nape of the neck and secured with sutures for direct conscious blood pressure measurements or drug delivery.
Telemetry.
Radiotelemetry transmitter catheters (Data Sciences International, St. Paul, MN) were surgically implanted in the femoral artery for continuous chronic blood pressure and heart rate (HR) recording. The radiotransmitter unit was then placed subcutaneously. After a 1-wk recovery period, arterial pressure and HR were recorded for 1 wk to obtain baseline recordings (measurements were taken for 10 s every 10 min, 24 h/day).
Viral microinjections.
After ≥1 wk of baseline blood pressure measurements, the rat was anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) and xylazine (7.5 mg/kg) and placed in a stereotaxic apparatus (David Kopf
Instruments, Tujunga, CA (8) . Microinjectors were removed 15 min after injection, the skin was sutured over the skull, and the animals were returned to their home cages.
Chronic PVN cannulas.
The rats were placed in a stereotaxic apparatus, and the skull was exposed. A small burr hole was hand-drilled in the skull for chronic placement of a cannula into the PVN (target: 2.0 mm caudal to bregma, 1.2 mm lateral to midline, and 7.4 mm ventral from the skull, 10° angle). Stainless steel screws and dental acrylic were used to anchor the cannulas into the skull, and the skin was sutured over the acrylic skull cap. monitored throughout the experimental protocol. The rat was allowed to recover for ≥2 days; then the same animal was subjected to the other treatment (losartan or aCSF). Throughout all studies, MAP and HR were continuously monitored. At the conclusion of the studies, histological analyses were performed to ensure PVN cannula placement.
Viral Studies Experimental Protocol
Contractility Studies
In another series of experiments, the adenovirus was microinjected into the PVN as stated above. At 7 and 10 days after viral injections, the animals were anesthetized using pentobarbital sodium (50 mg/kg ip). The superior mesenteric artery (SMA) was removed, cleaned of all connective tissue, and cut into helical strips for isometric contractility recordings. One strip from each set of animals was placed in a heated, aerated (95% O -5% CO ) tissue bath containing physiological salt solution (PSS; in mmol/l: 103 NaCl, 4. and 0.03 CaNa -EDTA, 37°C). Strips were placed under optimum resting tension (600 mg), equilibrated for 1 h, and challenged initially to PE (10 mol/l). Tissues were washed with PSS to allow tone to return to baseline.
Relaxation of the SMA (whereby strips were contracted to half-maximal concentration of PE) by exposure to norepinephrine (NE, 10 -3 × 10 mol/l), ANG II (10 -10 mol/l), and ACh (10 -10 mol/l) was used to examine any differences in responses between the SMA removed from animals treated with Ad-AT shRNA and animals treated with Ad-LacZ.
Histology
Rats were anesthetized with pentobarbital sodium (50 mg/kg ip) and perfused with 4% paraformaldehyde in 0.1 mol/l phosphate buffer. The brains were postfixed in 4% paraformaldehyde for 24 h at 4°C, transferred to 20% sucrose in 0.1 mol/l phosphate buffer, and stored at 4°C until analysis.
Paraformaldehyde-fixed brains were cut into serial sections (40 μm), placed onto slides, and allowed to dry overnight. On day 2, the slides were rinsed in
alcohol, 95% alcohol, 100% alcohol, and xylene (3 min each step). Slides were mounted and viewed under a microscope for staining.
β-Galactosidase Staining
Serial sections were stained for β-galactosidase activity using 5-bromo-4- 
Protein Isolation and Western Blot Analyses
Rats were anesthetized using pentobarbital sodium (50 mg/kg ip). The brains were quickly removed, immediately frozen on dry ice, and sectioned on a cryostat [PVN and supraoptic nucleus (SON) at 600 μm, SFO at 300 μm]. A microscope was used to localize the PVN, SON, and SFO, which were isolated using a tissue punch (17-gauge needle). The tissue was solubilized in lysis buffer [0.5 mmol/l Tris·HCl (pH 6.8), 10% SDS, and 10% glycerol] with protease inhibitors (0.5 mmol/l PMSF, 10 μg/μl aprotinin, and 10 μg/μl leupeptin). An ultrasonic processor was used to homogenize punches (1-2 s pulses, with intermediate vortexing), which were centrifuged for 10 min at 5,000 rpm at 4°C. Supernatant was collected, and protein concentration was determined using a bicinchoninic acid protein assay (Sigma).
Proteins ( 
Data Analysis and Statistics
Values are means ± SE. For comparison of two groups, the appropriate Student's t-test was used. For multiple comparisons, an ANOVA followed by a Student-Newman-Keuls post hoc test was used. For telemetry experiments using repeated measurements from the same animal, Proc Mixed and repeated-measures statistical analyses were performed using SAS statistical software (version 9.1). In all cases, P ≤ 0.05 was considered statistically significant.
RESULTS
Baseline Blood Pressure and HR
Blood pressure and HR were monitored with radiotelemeters prior to the viral injection and throughout the experimental protocol to determine if AT shRNA administered into the PVN altered resting parameters. To eliminate possible influences on baseline blood pressure during the days of agonist infusions, these time frames were not included in the overall basal blood pressure and HR data analysis. No observable differences in blood pressure and HR throughout the studies illustrate that AT shRNA had no basal effects on these parameters (Fig. 1, A and B ). There were also no changes in weight gain between the control (LacZ) and AT shRNA PVN-microinjected animals throughout the study (Fig. 1C) . 
Short-Term ANG II and PE-Induced Increases in Blood Pressure
During the experimental period, ANG II was infused intravenously for 1 h to acutely increase blood pressure. The infusions occurred 3, 7, 10, and 14 days after viral injections. At the end of the study, PE was infused for 30 min for evaluation of a different noncentrally mediated pressure response. At 3 days after PVN microinjection of AT shRNA or LacZ, a separation in the responsiveness to ANG II was evident (Fig. 2) . However, the overall one-way analysis of variance was not different between the groups of rats. Despite no significant difference in the peak change in blood pressure, a trend had begun for a reduced response to ANG II intravenous infusion in the AT shRNA PVN-microinjected animals compared with the LacZ-treated animals: 29 ± 6
vs. 21 ± 4 mmHg peak change in MAP (Fig. 2F) . The difference in ANG IIinduced increases in blood pressure were statistically significant by 7 days after viral injection. Throughout the ANG II intravenous infusion period, there was a significantly greater increase in acute ANG II-induced blood pressure in the control LacZ-than the AT shRNA-treated rats (Fig. 2B ): 32 ± 6 vs. 8 ± 9
mmHg peak change in MAP at 7 days (Fig. 2F) . These differences in acute ANG II-induced increases in blood pressure continued 10 and 14 days after viral injection (Fig. 2, C and D ): 35 ± 6 vs. 10 ± 6 mmHg and 32 ± 2 vs. 1 ± 5 mmHg peak change in MAP at 10 and 14 days, respectively (Fig. 2F) . The pressor response to ANG II in the LacZ-treated rats was not different. No significant changes in HR were observed during the ANG II infusions (Fig. 3 , At 3, 7, 10, and 14 days after viral injections, rats were challenged with a 1-h infusion of ANG II (30 ng·kg ·min , 15 μl/min). At the conclusion of the study (16 days after viral injection), PE was infused for 30 min (30 μg·kg ·min , 15 μl/min). There was no significant difference in heart rates over any of the experimental time points examined between the groups.
To further confirm that a reduction in AT R would alter acute ANG II-mediated elevations in blood pressure, bilateral cannulas were placed in the PVN for microinjections of losartan, an AT antagonist, into conscious male SpragueDawley rats prior to an acute ANG II-induced increase in blood pressure. The ANG II-induced elevation (69%) of blood pressure was significantly inhibited in animals pretreated with losartan compared with those treated with the aCSF vehicle (Fig. 4A) . In addition, losartan alone had no effect on basal blood pressure levels (data not shown). No overall differences in HR were observed; however, there was a trend for the reduction in HR to be greater in the losartan-treated animals than in those infused with aCSF ( Fig. 4B) . At the conclusion of the study, histological examination confirmed cannula placement localized to the PVN (Fig. 4C) . All injections that fell outside the PVN were excluded from the analyses. A: pretreatment (10 min) with losartan (20 nmol/l, 100-nl bilateral PVN injection) significantly blunted ANG II-induced (1 h, 30 ng·kg ·min ) increases in blood pressure compared with infusion of artificial cerebrospinal fluid (aCSF). Losartan alone had no effect on blood pressure (data not shown). B: pretreatment with losartan or aCSF did not alter heart rate during a 1-h infusion of ANG II or saline. C: schematic representation of 60-μm coronal sections through the PVN. Numbers below drawings indicate distance posterior to bregma according to the brain maps of Swanson (33a). ', Location at which cannulas terminated and losartan was infused. AHA, anterior hypothalamic area; SON, supraoptic nucleus; VMH, ventromedial hypothalamus. *P ≤ 0.05.
For further investigation of acute pressor responses, PE was infused for 30
min at the conclusion of the adenoviral study to evaluate a different pressor stimulus. There were no statistical differences in PE-induced changes in MAP between the animals treated with PVN-directed AT shRNA and those treated with LacZ, suggesting that the change in pressure was an ANG IImediated response (Fig. 2E) . In addition, no changes in HR were observed during the PE infusion (Fig. 3E) .
Isometric Contractility
Nearly complete suppression of the intravenous ANG II-induced increases in blood pressure following the inhibition of the PVN AT R was an unexpected result, since it is generally accepted that at least some component of the intravenous ANG II-induced increase in blood pressure is mediated through its vasoconstrictive effects (41). Therefore, even though the virus was specifically targeted to the PVN, it was important to determine that peripheral smooth muscle reactivity was not altered. In a separate group of animals, the SMA was isolated 7 and 10 days after virus injection to evaluate alterations in peripheral contractile responses to NE-and ANG II-induced relaxation, as well as ACh-induced relaxation. SMA isolated 7 or 10 days after viral / injections showed no significant differences in contraction to NE or ANG II or any differences in ACh-induced relaxation (Fig. 5) . These data confirm that the virus had no effect on SMA vascular reactivity and that, most likely, it was a centrally mediated event that was observed in prior experiments.
Fig. 5.
Superior mesenteric artery (SMA) was isolated from rats 7 and 10 days after PVN-targeted virus treatment for examination of potential alterations in peripheral contractile responses to relaxation induced by norepinephrine (NE; A and D) and ANG II (B and E), as well as by ACh (C and F). There were no significant differences in contraction or relaxation in SMA from rats treated with PVN-targeted AT shRNA vs. those treated with LacZ.
Confirmation of PVN Injections
At the conclusion of the studies, animals were perfused with 4%
paraformaldehyde, and the brains were removed for immunocytochemical analyses of AT Rs, histological staining, and staining for β-galactosidase (to identify the LacZ component of the adenovirus). Figure 6 demonstrates that the virus was targeted to the PVN, as indicated by blue staining throughout the PVN (Fig. 6, A and B) . Histological analysis confirmed that this was the To quantify any changes in AT expression and to ensure that the virus affected only the PVN, protein was isolated from the PVN, SFO, and SON from an additional set of animals 16-18 days after viral treatment, and AT protein was evaluated using Western blot analyses. AT protein expression in the PVN was reduced by 54% in animals subjected to PVN-targeted AT shRNA microinjection (Fig. 7A) compared with animals injected with LacZ.
Two other brain regions, the SFO and SON, were also examined for AT protein expression. The SFO and SON showed no difference in AT protein expression, suggesting that the virus had no effect in these brain regions. To ensure that an equal amount of protein was loaded, tubulin was used as a comparative measure, and no differences in tubulin expression were found between the experimental groups (Fig. 7) . 14, 18, 20) . Rostrally, CVOs that lie along the anterior third ventricle include the OVLT and SFO (1, 25) . Ablation of the anteroventral third ventricle, which includes the OVLT and the median preoptic area surrounding the anterior commissure, interferes with ANG II- 39.↵ ↵ Stocker SD, Toney GM. Median preoptic neurons projecting to the hypothalamic paraventricular nucleus respond to osmotic, circulating ANG II and baroreceptor input in the rat. 
